StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) After Speaking with Management
May 18, 2020 7:01 AM
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) following a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
May 18, 2020 2:17 AM
Keenly-watched COVID-19 vaccine 'won't be expensive', developer says
May 15, 2020 10:44 AM
Pfizer (PFE) DMD Data Fall Short of Bar Set by Sarepta (SRPT) - Baird
May 15, 2020 9:39 AM
Pfizer (PFE) Reports New Phase 1b Results of Gene Therapy in Ambulatory Boys with DMD Support Advancement into Pivotal Phase 3 Study
May 15, 2020 8:02 AM
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
May 15, 2020 8:00 AM
Pfizer (PFE) Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
May 14, 2020 10:01 AM
Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
May 14, 2020 10:00 AM
